By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Contents - p. 5 6. Forthcoming Issues - p. 7 7. Foreword: Biologics of IBD - p. 8 8. Preface: Biologic Therapy in Inflammatory Bowel Disease - p. 9 9. Immunology of Inflammatory Bowel Disease and Molecular Targets for Biologics - p. 10 10. Who Should Receive Biologic Therapy for IBD? - p. 21 11. Anti–Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD - p. 28 12. Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease - p. 35 13. An Update on Anti-TNF Agents in Ulcerative Colitis - p. 46 14. The Use of Biologic Agents in Pregnancy and Breastfeeding - p. 56 15. Risk of Infections with Biological Agents - p. 61 16. The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease - p. 70 17. Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy) - p. 79 18. Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring - p. 91 19. Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases - p. 100 20. Update on Janus Kinase Antagonists in Inflammatory Bowel Disease - p. 110 21. Update on Ustekinumab for the Treatment of Crohn's Disease - p. 119 22. Index - p. 125
No hay muestra disponible
No hay ficha técnica disponible
By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. Contents - p. 5 6. Forthcoming Issues - p. 7 7. Foreword: Biologics of IBD - p. 8 8. Preface: Biologic Therapy in Inflammatory Bowel Disease - p. 9 9. Immunology of Inflammatory Bowel Disease and Molecular Targets for Biologics - p. 10 10. Who Should Receive Biologic Therapy for IBD? - p. 21 11. Anti–Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD - p. 28 12. Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease - p. 35 13. An Update on Anti-TNF Agents in Ulcerative Colitis - p. 46 14. The Use of Biologic Agents in Pregnancy and Breastfeeding - p. 56 15. Risk of Infections with Biological Agents - p. 61 16. The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease - p. 70 17. Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy) - p. 79 18. Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring - p. 91 19. Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases - p. 100 20. Update on Janus Kinase Antagonists in Inflammatory Bowel Disease - p. 110 21. Update on Ustekinumab for the Treatment of Crohn's Disease - p. 119 22. Index - p. 125
No hay muestra disponible
No hay ficha técnica disponible
